Kapila K. Anand - 30 Jun 2026 Form 4 Insider Report for Elanco Animal Health Inc (ELAN)

Reporting relationship: Director
Issuer ticker: ELAN
Reported as of: 30 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Jul 2026, 16:49:17 UTC
Prior SEC filing: 09 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Amy C. Seidel, as Attorney-in-Fact for Kapila K. Anand

Key filing fact

Kapila K. Anand filed Form 4 for Elanco Animal Health Inc (ELAN) on 02 Jul 2026.

Key facts

This page summarizes Kapila K. Anand's Form 4 filing for Elanco Animal Health Inc (ELAN).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 02 Jul 2026, 16:49.

Change

Previous filing in this sequence was filed on 09 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001679166 Primary reporting owner

Anand Kapila K

Relationship: Director
Address: C/O ELANCO ANIMAL HEALTH INCORPORATED, 450 ELANCO CIRCLE, INDIANAPOLIS
Signature: /s/ Amy C. Seidel, as Attorney-in-Fact for Kapila K. Anand
Signature date: 02 Jul 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ELAN transaction Derivative

Deferred Stock Units

Award

Transaction value
Shares: +584
Change %: +6.2%
Price: $24.61^*
Shares after: 10,080
Date: 30 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 584
Exercise price
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Ms. Anand elected to defer her director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock.

Footnote F2

The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan.

Footnote F3

The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $24.61 on June 30, 2026.